252061-94-2

Basic information

• Product Name: 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline
• Synonyms: 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline;6-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline
• CAS NO: 252061-94-2
• Molecular Formula: C₁₆H₁₇NO
• Molecular Weight: 239.31228
• EINECS: -0
• Mol File: 252061-94-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 400.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.102±0.06 g/cm3(Predicted)
• PKA: 9?+-.0.20(Predicted)
• CAS DataBase Reference: 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline(252061-94-2)
• EPA Substance Registry System: 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline(252061-94-2)

Safety Data

• Hazardous Substances Data: 252061-94-2(Hazardous Substances Data)

Usage

General Description

7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline is a chemical compound with the molecular formula C21H21NO. It is a member of the tetrahydroisoquinoline family, which is known for its diverse biological activities. This particular compound has been studied for its potential use in the pharmaceutical industry, particularly in the development of new drugs for various medical conditions. It has been found to exhibit promising properties, including antioxidant and antifungal activities, making it a target for further research and potential therapeutic applications. The presence of the benzyloxy group in its structure adds to its potential as a pharmacological agent. Overall, 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline is an intriguing chemical compound with potential pharmaceutical applications that warrant further investigation.

Upstream product

• 50-00-0 formaldehyd 
• 51179-05-6 2-(4-(benzyloxy)phenyl)ethanamine 
• 100-39-0 benzyl bromide 
• 164148-88-3 6-benzyloxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 59839-23-5 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 591-31-1 3-methoxy-benzaldehyde 

Downstream Products

• 1429253-97-3 C₂₈H₂₆N₄O₂ 
• 1064200-16-3 2-(3,5-dimethoxybenzoyl)-6-O-sulfamoyl-1,2,3,4-tetrahydroisoquinoline 
• 1064200-01-6 2-(3,5-dimethoxybenzoyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-65-8 6-benzyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-66-9 6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 94086-31-4 6-hydroxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064199-80-9 6-benzyloxy-2-(3,5-dimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064197-69-8 6-benzyloxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 189572-92-7 {6-[4-(tert-butoxycarbonylamino-imino-methyl)-benzyloxy]-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 164148-90-7 [6-(4-cyano-benzyloxy)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 164148-85-0 (6-benzyloxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester 

Relevant articles and documents

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Design and Synthesis of Potent, Selective Inhibitors of Protein Arginine Methyltransferase 4 against Acute Myeloid Leukemia

PRMT4 is a type I protein arginine methyltransferase and plays important roles in various cellular processes. Overexpression of PRMT4 has been found to be involved in several types of cancers. Selective and in vivo effective PRMT4 inhibitors are needed for demonstrating PRMT4 as a promising therapeutic target. On the basis of compound 6, a weak dual PRMT4/6 inhibitor, we constructed a tetrahydroisoquinoline scaffold through a cut-and-sew scaffold hopping strategy. The subsequent SAR optimization efforts employed structure-based approach led to the identification of a novel PRMT4 inhibitor 49. Compound 49 exhibited prominently high potency and selectivity, moderate pharmacokinetic profiles, and good antitumor efficacy in acute myeloid leukemia xenograft model via oral administration, thus demonstrating this compound as a useful pharmacological tool for further target validation and drug development in cancer therapy.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.